Heart risks during CAR T-Cell therapy under the microscope
NCT ID NCT04026737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys before and after treatment. The goal was to learn how often heart problems occur and who might be at higher risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors identify which patients are at higher risk for heart problems during CAR T-cell therapy, leading to better monitoring and care.
- What could go wrong
- This is a small, observational study with only 44 participants, so results may not apply to everyone. It does not test a new treatment, so it won't directly improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?